A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-16

Study Completion Date

2024-10-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment). For more information, please visit the trial's website www.adamclinicaltrial.com (only applicable in the US).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Interest of Clomiphene Citrate in Patients With Non-obstructive Azoospermia on the Quantity of Sperm Cells

NCT03615547

Azoospermia, Nonobstructive

NOT_YET_RECRUITING PHASE3

Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men

NCT03455075

Healthy Men Male Contraception

COMPLETED PHASE2

Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.

NCT02641769

Non-obstructive Azoospermia

UNKNOWN PHASE1/PHASE2

Royal Jelly Supplementation in Unexplained Male Infertility

NCT07337265

Unexplained Infertility Male Infertility Sperm DNA Fragmentation

NOT_YET_RECRUITING NA

Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism

NCT02137265

Non Obstructive Azoospermia Hypogonadism

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Male Idiopathic Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FE 999049 (Follitropin Delta)

Group Type EXPERIMENTAL

FE 999049

Intervention Type DRUG

FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FE 999049

FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.

Intervention Type DRUG

Placebo

Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

REKOVELLE Follitropin Delta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of infertility with current partner at randomisation must be 12-60 months if current partner is aged \<35 years or 6-60 months if current partner is aged 35-38 years.
* Men between the ages of 18 and 50 years.
* Total sperm count 5-39 million at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
* Total sperm motility of ≥10% at screening; confirmed by two samples taken ≥2 weeks apart before randomisation. If a semen sample has been taken within 3 months prior to screening and been analysed at an andrology laboratory, it can be included as the first of the two semen samples at screening.
* Semen volume ≥1.4 mL at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
* Serum follicle-stimulating hormone (FSH) levels of 2-12.0 IU/L (measured at central laboratory) at screening)
* Serum luteinising hormone (LH) levels of 1.2-7.5 IU/L (measured at central laboratory) at screening.
* Serum total testosterone levels of ≥300 ng/dL (equals ≥10.4 nmol/L; measured at central laboratory) at screening.
* Agree to have regular intercourse with current female partner with the intent of spontaneous conception within 9 months from randomization.
* Agree to provide information on female partner's positive urine pregnancy test(s) and documentation of ultrasound(s), delivery, and neonatal/infant health.

Current partner fulfilling the criteria below:

* Pre-menopausal woman between the ages of 18 and 38 years (both inclusive) at the time of randomisation of male participant.
* Regular menstrual cycles of 21-35 days.
* No history or current condition of pelvic inflammatory disease, endometriosis stage II-IV by definite or empirical diagnosis, or tubal ligation.
* Agree not to obtain infertility treatment outside of this trial for 6 months from randomization of male subject.

Exclusion Criteria

* Previous FSH treatment for ≥4 months not leading to conception.
* Past or current use of finasteride within 3 months prior to screening.
* Any history of anatomical disorder of the pituitary gland or testes.
* Any structural abnormalities of the vas deferens (unilateral or bilateral) at screening.
* Any known, clinically significant, systemic disease in addition to the trial indication that might negatively impact fertility.
* Known history or presence of clinical varicocele (subclinical and Grade 1 varicocele are acceptable).
* Known history of cryptorchidism, testicular torsion, or orchitis.
* Known abnormal karyotype (including Y-chromosome microdeletion).
* Current or past treatment of urogenital (kidney, bladder, testicular, or prostate) cancer as well as history of chemo- or radiotherapy that can have impact on testes.
* Any known uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders).
* Administration of hormonal preparations, agents known to impair testicular function or affect sex hormone secretion, and known or suspected teratogens within 3 months prior to screening. Administration of anabolic steroids within 12 months prior to screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No